TGA: On-going use of Remote Inspections
![Data Integrity Master Class with full-day pre-course session Raw Data](files/eca/userImages/training.img/Z-ECA-Raw-Data-Data-Integrity-Masterclass.jpg)
Recommendation
27-30 August 2024
Copenhagen, Denmark
including 8 Interactive Workshops
Due to the ongoing pandemic, the Australian Therapeutic Goods Administration (TGA) had suspended its overseas GMP inspections. Like many other authorities, the TGA is currently working its way through a large number of certification applications. As international travel restrictions remain in place, the remote GMP inspection programme will continue, as the TGA currently notes on its website. This means remote inspections remain the only available option for certification applications during the pandemic. Now, sponsors with submitted applications for inspection will no longer be contacted individually.
Prioritisation of remote GMP inspections for overseas manufacturers will be based on the following criteria:
- the ability to use the alternative GMP Clearance processes
- current compliance information
- applications for marketing authorisation
What does this "GMP Clearance" mean?
The TGA is in contact with international partner authorities to understand the different approaches taken to GMP inspections. This information is evaluated and its implications for the TGA's own GMP clearance procedure are considered.
A Compliance Verification (CV) pathway is also in place for this purpose. Sponsors can still use the GMP clearance questionnaire for manufacturers who had an on-site inspection in 2018/2019.
It is important to note that inspection reports issued after a remote inspection or assessment are not accepted as primary evidence of GMP Clearance, i.e. they do not replace the inspection report of a physical on-site inspection.
If applicants have already used the questionnaire option for GMP Clearance, a TGA remote inspection will most likely be required for any further application.
To support industry, during the COVID 19 pandemic, the TGA introduced a temporary change to the documentation requirements for GMP Clearance applications submitted via the above Conformity Verification (CV) route.
To support a GMP Clearance application, applicants may submit a recently expired inspection report from a recognised regulatory authority and a GMP Clearance questionnaire, as well as any additional documents identified when completing the questionnaire. GMP Clearance applications are then evaluated using a risk-based approach.
Related GMP News
24.07.2024FDA Warning Letter to a Manufacturer of an Athlete Muscle Maintenance Creme
24.07.2024FDA describes detailed CAPA Procedure in Warning Letter
17.07.2024Congressional Scrutiny on FDA's Foreign Inspection Program puts Pressure on Agency
19.06.2024More FDA Inspections again - also in the EU?
12.06.2024GMP Problems with critical Medicinal Products - what now?
15.05.2024Lack of Quality Oversight: EU Non-Compliance Report issued to Omeprazole Manufacturer